A Physiologically Based Pharmacokinetic Modeling Approach to Predict Disease–Drug Interactions: Suppression of CYP3A by IL-6

Interleukin-6 and cytochrome-P450, reason for concern?

(2012) Sooha Kim et al.   RHEUMATOLOGY INTERNATIONAL

Disease–Drug–Drug Interaction Involving Tocilizumab and Simvastatin in Patients With Rheumatoid Arthritis

(2011) C Schmitt et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

How Current Understanding of Clearance Mechanisms and Pharmacodynamics of Therapeutic Proteins Can Be Applied for Evaluation of Their Drug-Drug Interaction Potential

(2011) E. Kraynov et al.   DRUG METABOLISM AND DISPOSITION

Effects of Interleukin-6 (IL-6) and an Anti-IL-6 Monoclonal Antibody on Drug-Metabolizing Enzymes in Human Hepatocyte Culture

(2011) L. J. Dickmann et al.   DRUG METABOLISM AND DISPOSITION

Prediction of time-dependent CYP3A4 drug–drug interactions by physiologically based pharmacokinetic modelling: Impact of inactivation parameters and enzyme turnover

(2011) K. Rowland Yeo et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

Changes in expression of hepatic cytochrome P450 subfamily enzymes during development of adjuvant-induced arthritis in rats

(2011) Hisakazu Sanada et al.   JOURNAL OF TOXICOLOGICAL SCIENCES

CYP-Mediated Therapeutic Protein-Drug Interactions

(2010) Jang-Ik Lee et al.   CLINICAL PHARMACOKINETICS

Therapeutic Protein–Drug Interactions and Implications for Drug Development

(2010) S-M Huang et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

The Correlation between Increased Serum Concentrations of Interleukin-6 Family Cytokines and Disease Activity in Rheumatoid Arthritis Patients

(2010) Soo-Jin Chung et al.   YONSEI MEDICAL JOURNAL

Predicting Drug–Drug Interactions: An FDA Perspective

(2009) Lei Zhang et al.   AAPS Journal

Impact of Infectious and Inflammatory Disease on Cytochrome P450–Mediated Drug Metabolism and Pharmacokinetics

(2009) ET Morgan   CLINICAL PHARMACOLOGY & THERAPEUTICS

Physiologically based mechanistic modelling to predict complex drug–drug interactions involving simultaneous competitive and time-dependent enzyme inhibition by parent compound and its metabolite in both liver and gut—The effect of diltiazem on the time-course of exposure to triazolam

(2009) Karen Rowland Yeo et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

The Simcyp®Population-based ADME Simulator

(2009) Masoud Jamei et al.   Expert Opinion on Drug Metabolism & Toxicology

Overnight variations in cortisol, interleukin 6, tumour necrosis factor   and other cytokines in people with rheumatoid arthritis

(2008) M G Perry et al.   ANNALS OF THE RHEUMATIC DISEASES

Pre-analytical and biological variability in circulating interleukin 6 in healthy subjects and patients with rheumatoid arthritis

(2008) Lene S. Knudsen et al.   BIOMARKERS

Lack of Pharmacokinetic Interaction of Mipomersen Sodium (ISIS 301012), a 2′-O-Methoxyethyl Modified Antisense Oligonucleotide Targeting Apolipoprotein B-100 Messenger RNA, with Simvastatin and Ezetimibe

(2008) Rosie Z Yu et al.   CLINICAL PHARMACOKINETICS

Regulation of Drug Transporter Expression in Human Hepatocytes Exposed to the Proinflammatory Cytokines Tumor Necrosis Factor-  or Interleukin-6

(2008) M. L. Vee et al.   DRUG METABOLISM AND DISPOSITION

Decreased dromotropic response to verapamil despite pronounced increased drug concentration in rheumatoid arthritis

(2003) Patrick R. Mayo et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY